| 1 |
Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, Serrero M, Leclerc E, Caillo L, Pereira B, Amiot A, Bouguen G. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther 2023;57:676-88. [PMID: 36401585 DOI: 10.1111/apt.17305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, Narula N, Tsai C, Peerani F, Reise-Filteau M, Bressler B, Starkey SY, Loomes D, Sedano R, Jairath V, Bessissow T; Canadian IBD Research Consortium. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study. Am J Gastroenterol 2023. [PMID: 36580497 DOI: 10.14309/ajg.0000000000002129] [Reference Citation Analysis]
|
| 3 |
Perin RL, Magro DO, Andrade AR, Argollo M, Carvalho NS, Damião AOMC, Dotti AZ, Ferreira SDC, Flores C, Ludvig JC, Nones RB, Queiroz NSF, Parra RS, Steinwurz F, Teixeira FV, Kotze PG. Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study. Crohns Colitis 360 2023;5:otac050. [PMID: 36777366 DOI: 10.1093/crocol/otac050] [Reference Citation Analysis]
|
| 4 |
Chaparro M, Acosta D, Rodríguez C, Mesonero F, Vicuña M, Acosta MB, Fernández-Clotet A, Martínez ÁH, Arroyo M, Vera I, Ruiz-Cerulla A, Sicilia B, Cabello Tapia MJ, Villafranca CM, Castro-Poceiro J, Cadilla JM, Sierra-Ausín M, Vázquez Morón JM, Lidón RV, Bermejo F, Royo V, Calafat M, González-Muñoza C, Carnerero EL, Marcos NM, Torrealba L, Alonso-Galán H, Benítez JM, Nieto YB, Diz-Lois Palomares MT, García MJ, Muñoz JF, Armesto González EM, Calvet X, Hernández-Camba A, Madrigal Domínguez RE, Menchén L, Pérez Calle JL, Piqueras M, Sadornil CD, Botella B, de Jesús Martínez-Pérez T, Ramos L, Rodríguez-Grau MC, San Miguel E, Fernández Forcelledo JL, Fradejas Salazar PM, García-Sepulcre M, Gutiérrez A, Llaó J, Abizanda ES, Boscá-Watts M, Iyo E, Keco-Huerga A, Bonil CM, González EP, Pérez-Galindo P, Varela P, Gisbert JP. Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety. Am J Gastroenterol 2022. [PMID: 36716287 DOI: 10.14309/ajg.0000000000002145] [Reference Citation Analysis]
|
| 5 |
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program. J Crohns Colitis 2022:jjac141. [PMID: 36124702 DOI: 10.1093/ecco-jcc/jjac141] [Reference Citation Analysis]
|
| 6 |
Zhang T, Zhang B, Tian W, Wang F, Zhang J, Ma X, Wei Y, Tang X. Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021. Front Pharmacol 2022;13:951004. [DOI: 10.3389/fphar.2022.951004] [Reference Citation Analysis]
|
| 7 |
Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. JCM 2022;11:5267. [DOI: 10.3390/jcm11185267] [Reference Citation Analysis]
|
| 8 |
Minnis-Lyons SE, Aiken Z, Chow S, Din S. Managing IBD in patients with previous cancers. Frontline Gastroenterol 2022;13:e44-50. [PMID: 35812021 DOI: 10.1136/flgastro-2022-102187] [Reference Citation Analysis]
|
